Peripheral nerve myelination is adversely affected in the most common form of the hereditary peripheral neuropathy called Charcot-Marie-Tooth Disease. This form, classified as CMT1A, is caused by a 1.4 Mb duplication on chromosome 17, which includes the abundantly expressed Schwann cell myelin gene, Peripheral Myelin Protein 22 (PMP22). This is one of the most common copy number variants causing neurological disease. Overexpression of Pmp22 in rodent models recapitulates several aspects of neuropathy, and reduction of Pmp22 in such models results in amelioration of the neuropathy phenotype. Recently we identified a potential super-enhancer approximately 90-130 kb upstream of the Pmp22 transcription start sites. This super-enhancer encompasses a cluster of individual enhancers that have the acetylated histone H3K27 active enhancer mark, and coincides with smaller duplications identified in patients with milder CMT1A-like symptoms, where the PMP22 coding region itself was not part of the duplication. In this study, we have utilized genome editing to create a deletion of this super-enhancer to determine its role in Pmp22 regulation. Our data show a significant decrease in Pmp22 transcript expression using allele-specific internal controls. Moreover, the P2 promoter of the Pmp22 gene, which is used in other cell types, is affected, but we find that the Schwann cell-specific P1 promoter is disproportionately more sensitive to loss of the superenhancer. These data show for the first time the requirement of these upstream enhancers for full Pmp22 expression.
Introduction
The integrity of the peripheral nervous system (PNS) depends on the coordination of peripheral nerve axons and the resident myelin-producing glia called Schwann cells. Axonal signaling to Schwann cells promotes myelination (1, 2) , and Schwann cells in return provide trophic support to axons (3) and enable the rapid saltatory conduction on which PNS function relies. This coordination is compromised in hereditary motor and sensory neuropathies of the peripheral nervous system, which comprise the family of disorders broadly called Charcot-Marie-Tooth disease (CMT) (4) . CMT affects up to 1 in 2500 people (5) and is characterized by progressive distal limb muscle atrophy and weakness.
The most common subtype of CMT, called CMT Type 1A (CMT1A), accounting for 40-50% of CMT cases, results from a 1.4 Mb duplication on chromosome 17 which includes the myelin gene Peripheral Myelin Protein 22 (PMP22) (6) (7) (8) (9) . The reciprocal 1.4 Mb deletion is also linked to a second distinct disease, hereditary neuropathy with liability to pressure palsies (HNPP) (10) .
Later transgenic studies linked aberrant Pmp22 expression to peripheral neuropathy in rodent models of CMT1A (11) , and studies of knockout alleles revealed symptoms in the Pmp22 heterozygotes that resemble aspects of HNPP (12) (13) (14) . Furthermore, in rodent models of Pmp22 overexpression, reduction of the Pmp22 transcript has been shown to ameliorate the symptoms of neuropathy (15) (16) (17) (18) , indicating that transcriptional regulation is a valid target of therapies for CMT1A, and drug screening assays have been set up to identify transcriptional modulators of Pmp22 (19, 20) . Together, these studies highlight the importance of proper Pmp22 gene dosage and a need to understand the endogenous regulatory mechanisms that establish and maintain this proper dosage.
The existence of distal regulatory elements for Pmp22 was first suggested by transgenic studies of Pmp22 promoter regions, which are able to drive low levels of Schwann cell expression of a reporter but are not greatly increased as the native gene is during the course of myelination (8, 21, 22) . Subsequently, patients presenting with mild CMT-like symptoms were found to possess duplications of either 186 or 194 kb upstream of Pmp22 but not including the gene itself (23, 24) . Within the 168 kb overlapping sequence shared by these duplications were a number of conserved noncoding sequences that could be potential regulatory elements (24) . Accordingly, chromatin immunoprecipitation (ChIP) analysis identified high levels of H3K27 acetylation (H3K27ac) (25, 26) , a histone mark associated with active enhancers (27) , and binding sites for transcription factors that regulate Pmp22 and other genes in the myelination program (25, 28, 29) , such as SOX10 (30, 31) , EGR2/KROX20 (32) (33) (34) (35) and the Hippo pathway factor TEAD1 (29) , within this distal region. Moreover, formaldehyde assisted isolation of regulatory elements (FAIRE) showed that the sites are found within open chromatin, which is another hallmark of enhancer regions. Finally, evidence from nerve injury models established a correlation between the status of these elements and Pmp22 expression; following peripheral nerve injury, many of the H3K27ac marks within this region disappear (26) , and there is a concurrent down-regulation of Pmp22 transcription (36) .
The most prominent SOX10/EGR2 binding sites within this region could drive expression in reporter assays (37) . However, this work did not directly test if these putative enhancers, which are spread across approximately 30 kb and located around 100 kb away from the gene itself, contribute to Pmp22 expression in their native genomic context. Therefore, we sought to test the contribution of this enhancer cluster by evaluating the consequences of inducing a deletion that would include these enhancers.
Results

Analysis of distal Pmp22 enhancer region as superenhancer
Genome-wide analysis of enhancers has identified large regions of noncoding DNA with the hallmarks of regulatory elements, called super-enhancers (38) . Super-enhancers are defined as extended genomic regions that contain multiple constituent enhancers separated by <12.5 kb. A super-enhancer's constituent enhancers display enrichment of measures of enhancer status and function such as DNase I hypersensitivity, the enhancer-associated histone mark H3K27ac, and the binding of transcription factors at a higher degree than those found in typical enhancers. In general, super-enhancers are primarily involved in the regulation of genes essential for cell identity.
The enhancer-rich region upstream of the Pmp22 gene was identified as a super-enhancer by assessing ChIP-seq occupancy of H3K27 acetylation. In the resulting distribution, 1694 superenhancer domains were delineated from peaks corresponding to typical enhancers by establishing a threshold where the slope of the plot of super-enhancer score by ranked peaks exceeds 1 (Fig. 1A) , and we selected a high confidence list of 1170 superenhancers that have >1000 normalized reads (Supplementary Material, Table S1 ). Mapping of these peaks revealed an approximately 37 kb super-enhancer domain upstream of the Pmp22 gene (hereafter referred to as Pmp22-SE) containing as many as six constituent enhancers, including previously described EGR2 and SOX10 binding sites labeled A, B and C (Fig. 1B) . This domain falls within the smallest region of overlap for the previously-described intergenic duplications associated with mild forms of CMT (24) . Analysis of an existing adult sciatic nerve ChIP-seq data set (39) for H3K4 trimethylation (H3K4me3), a histone mark associated with active promoters (40) , was used to evaluate activity of nearby genes (Fig. 1C) ; these data demonstrate that the two genes nearest Pmp22-SE, CMT1A duplicated region transcript 4 (Cdrt4) and Tektin 3 (Tekt3), are transcriptionally silent in peripheral nerve, and that the closest expressed genes are Pmp22 and trans-golgi network vesicle protein 23 homolog B (Tvp23b), a gene of unknown function.
Deletion of Pmp22-SE by CRISPR-Cas9
To evaluate the in situ function of Pmp22-SE, we employed the CRISPR-Cas9 system to induce a large deletion that would remove the major enhancers within Pmp22-SE. As has been demonstrated previously (41) , the simultaneous induction of double-stranded breaks at two points on the same chromosome by CRISPR-Cas9 complexes can be used to trigger a large deletion of the intervening sequence. We used the same approach to delete Pmp22-SE in a modified clone of the S16 rat Schwann cell line. The rat S16 Schwann cell line is a useful experimental model for studying myelin gene expression because it expresses several myelin genes, including Pmp22, at levels near those found in myelinating Schwann cells in vivo (42) . Moreover, studies of regulation in the S16 cell line have shown many similarities in transcription factor binding in the S16 cell line compared to in vivo ChIP analysis of rat peripheral nerve (29, 34, 37, 43, 44) .
Since deletion may not occur readily on all copies, we chose to use a variant clone of the immortalized S16 rat Schwann cell line (45) in which one of the Pmp22 alleles contains two reporters inserted by genome editing ( Fig. 2A) . Similar clones were prepared for reporter-based drug screens (19) , and the firefly luciferase and secreted nanoluciferase reporter open reading frames are separated from the Pmp22 open reading frame and from each other by intervening 2a ribosome stuttering sequences (46) . Sequencing of PCR products spanning the insert junctions showed that reporters had been incorporated just downstream of the Pmp22 open reading frame in the last exon (Supplementary Material, Fig. S1A ). However, the 3 0 UTR of the Pmp22 gene is retained in order to minimize any changes to transcript stability and processing. As Pmp22 is transcribed along with the reporters in a single mRNA on this copy, we can use quantitative RT-PCR to distinguish between the two resulting species of Pmp22 allele, (henceforth referred to as either the wild-type or reporter alleles).
Using this S16 clone with a reporter-tagged allele, the deletion of the super-enhancer was created by transfecting with plasmids that express both the Cas9 protein and the sgRNA targeting sequences approximately 38 kb apart. Included within this region are the previously-analyzed elements A, B and C at À120 kb, À115 kb and À91 kb, respectively, as well as a potential elements marked by H3K27ac at À128 kb, À108 kb, and À104 kb. Using primer combinations that flank the anticipated repair junction resulting from deletion of Pmp22-SE (Fig. 2B) , we successfully amplified a unique PCR product resulting from this deletion in the pool of transfected cells as well as in a subset of clonal lines isolated from this pool by single-cell sorting (Fig. 2C) . The anticipated repair junction was confirmed using Sanger sequencing (Supplementary Material, Fig. S1B ). Screening of 72 clonal lines yielded eight clones in which the deletion could be detected. However, we could also amplify a PCR product with primers flanking each individual sgRNA targeting site in these clones (data not shown), indicating that we did not achieve homozygous deletion of Pmp22-SE on all copies of chromosome 10.
Karyotyping of the S16 cell line revealed that the line is polyploid, with an average of three copies of each chromosome, including chromosome 10 where the Pmp22 gene is located (Supplementary Material, Fig. S2 ). To determine the number of copies possessing the deletion in each clone, quantitative PCR was performed using two primer sets targeting separate regions both inside and outside of the target region (Fig. 2D) . Representative results from the parent reporter line were compared to results from three clones C6-C8 in which the deletion could be detected. Clones C6-C8 displayed normalized copy number reduction of approximately 70% compared to the average value of clones C1-C5, suggesting that these clones possess deletions of Pmp22-SE on two of the three copies of chromosome 10.
Pmp22-SE is required for full Pmp22 expression
Since the overall level of Pmp22 expression was reduced in these clones (not shown), we aimed to determine if this effect was allele-specific, since that would provide a useful internal control for the potential obfuscating effects of clone-to-clone variation in Pmp22 expression. Levels of Pmp22 mRNA were determined via quantitative real-time reverse transcription PCR (qRT-PCR) using primers that differentiate the wild-type and reporter alleles (Fig. 3A) . Using this method, we found that the three clones C6-C8 presented here displayed an approximate two-fold reduction in Pmp22 transcription exclusively on the wild-type alleles relative to the five 'deletion-negative' clones C1-C5 when normalizing the results to the housekeeping gene Actb (Fig. 3B) , indicating that this super-enhancer is required for full activation of Pmp22 transcription. In contrast, the expression of the reporter allele was not affected, indicating that the deletions on 2 of the 3 copies occurred on the wild-type alleles of Pmp22.
As the negative clones C1-C5 show some evidence of variation in myelin gene regulation such that Pmp22 expression and myelin genes Mpz and myelin-associated glycoprotein (Mag). In all cases, expression levels are shown relative to the average of clones C1-C5, which was set as 1. Error bars represent the standard deviation of three independent measurements for clones C1 and C3-C8 and two measurements for clone C2. Statistical analysis denotes results for biological replicates comparing the mean of the zero-deletion clones (n ¼ 5) to the mean of the two-deletion clones (n ¼ 3) (*P < 0.05).
varies by as much as 30% when normalized to Actb expression, we also normalized expression of Pmp22 to expression of the highly expressed myelin protein zero (Mpz) gene (Fig. 3C) , which is regulated by many of the same transcription factors as Pmp22 (35, 43) and would therefore be expected to show similar changes in expression if the reduced expression in clones C6-C8 is due to upstream differences in pro-myelinating transcription factors. A similar allele-specific reduction of Pmp22 was observed using Mpz normalization with an apparent reduction in clone-to-clone variability, while the normalized reporter allele expression was unchanged from parental and control lines.
While our analysis employed three independent clones in which 2 of the 3 Pmp22 alleles had deletion of the superenhancer, we had also obtained clones C11 and C12 in which 1 of the 3 alleles have a similar deletion of Pmp22-SE ( Supplementary  Material, Fig. S3 ). C11 displayed an approximate 25% reduction of Pmp22 levels specific to the wild-type alleles, while expression from the reporter allele was unchanged compared to the parental cell line and clone C10, in which no deletion could be detected. These data suggest that one of C11's two wild-type alleles possesses a deletion of Pmp22-SE. By contrast, clone C12 displayed a 50% reduction of Pmp22 levels unique to the reporter allele with unaffected wild-type allele expression, indicating that the deletion of Pmp22-SE occurred on the reporter allele in this clone. Together, these data are consistent with the conclusion that each copy of Pmp22-SE is responsible for approximately half of Pmp22 transcription from the copy of chromosome 10 on which it is located.
To evaluate whether these effects were specific to Pmp22, we measured expression of other myelin genes Mpz and myelinassociated glycoprotein (Mag), which are regulated by similar transcription factors like SOX10 and EGR2 (28) . The reduction of expression appears unique to Pmp22, as other myelin genes displayed no consistent trend in expression relative to the negative clones (Fig. 3D) . As an additional measure of specificity, we analyzed expression of the gene Tvp23b, which is located approximately 100 kb upstream of Pmp22-SE and is therefore the second most proximal expressed gene to the super-enhancer, in order to determine whether Pmp22-SE's apparent regulation of Pmp22 was potentially due to proximity. As with Mpz and Mag, deletion of Pmp22-SE had no apparent effect on Tvp23b expression, demonstrating that this region specifically regulates Pmp22.
Regulation of the Schwann cell-specific P1 promoter by Pmp22-SE Pmp22 is primarily transcribed using one of two alternative promoters (47) . The P1 promoter driving exon 1A expression is largely Schwann cell-specific and accounts for half of Schwann cell Pmp22 transcripts in humans and $75% of transcripts in rodents. The P2 promoter driving exon 1B-containing transcripts is the primary promoter used in other tissues in which Pmp22 is transcribed, and also drives the majority of Pmp22 transcription in cultured Schwann cell lines including S16 cells (42) . Both promoters are developmentally regulated in peripheral nerve (47) , and Pmp22-SE's constituent enhancers are marked by H3K27ac as early as postnatal day one (29); however, Pmp22-SE is particularly correlated with the P1 promoter, as other cell types such as oligodendrocytes that transcribe Pmp22 only through the P2 promoter also lack this enhancer cluster (29) .
Therefore, we tested whether deletion of Pmp22-SE displayed differential effects on transcripts from each promoter.
As P2-driven expression accounts for the vast majority of transcripts in our cell lines, the expression level of this transcript mirrors the trend in overall Pmp22 expression; in clones possessing two deletions of Pmp22-SE, we found that P2 transcripts are down approximately two-fold when normalized to both Actb (Fig. 4A) and Mpz (Fig. 4B) . However, we found that loss of two copies of Pmp22-SE dramatically reduced expression of the Schwann cell-specific P1 promoter.
Because these promoter-specific data would reflect all three copies of Pmp22, we sought to independently measure promoter-specific transcription in an allele type-specific manner. We performed qRT-PCR with primer sets spanning the ORF of Pmp22 so that we could differentiate P1 and P2 transcripts in both wild-type and reporter alleles (Fig. 4C) . Since the PCR products would be approximately 450 bp in length, we utilized relative standard curve analysis to correct for the reduced amplification efficiency of these PCR products. We found that these results were consistent with our earlier observations; P1-driven transcription on the wild-type alleles was greatly reduced, while P1-driven transcripts from the reporter allele were slightly reduced, though still comparable to the range of P1 transcription observed in our negative clones (Fig. 4D) . Similarly, our measurements show that the observed reduction of P2-driven transcription is only present on the wild-type alleles (Fig. 4E) .
Regulation of the Pmp22 gene by YY1
Recent studies of enhancer-promoter looping have identified the YY1 transcription factor as critical factor in mediating the function of such loops (48) . The YY1 transcription factor was previously shown to regulate Pmp22 expression with Schwann cell-specific deletion of the YY1 gene (49), and we reasoned that YY1 may promote formation of the predicted loop between the Pmp22 gene and the distal Pmp22-SE. Accordingly, YY1 binding in the PMP22 promoter and super-enhancer regions has been detected by ChIP in the ENCODE profiles of transcription factor binding (50, 51) . Therefore, we used YY1 siRNA to downregulate YY1 levels in the C6 clone and the parental cell line, and as predicted from the in vivo studies (49) , there was a significant reduction of both wild type and reporter alleles of Pmp22 in the parental line compared to control siRNA (Fig. 5A) . Similarly, transcription from both promoters was dramatically reduced (Fig. 5B) . As the reporter and wild type alleles were both sensitive to loss of YY1 in this clone, these data suggest that the role of YY1 in Pmp22 regulation is not strictly limited to bridging the distal super-enhancer and the Pmp22 gene.
Discussion
The dosage-sensitive nature of the Pmp22 gene demonstrates the importance in establishing the correct expression level of this gene. This is especially true in light of the identification of duplications that cause mild CMT-like symptoms without including the gene itself (23, 24) . Here, we report the characterization of a distal Pmp22 super-enhancer that coincides with these observed duplications and provides an explanation for how these duplications produce CMT-like symptoms.
In this study, we analyzed existing ChIP-seq data sets (26, 28, 29) and employed the genome editing CRISPR-Cas9 system to identify and delete this super-enhancer in vitro. Pmp22-SE drives approximately half of Pmp22 transcription in this Schwann cell culture model. We presume that the residual amount of Schwann cell Pmp22 expression is accounted for by other enhancers outside of Pmp22-SE. In addition to the late myelination Schwann cell-specific element (LMSE) upstream of the P1 Pmp22 promoter (22), a highly EGR2-responsive element at þ11 kb within Pmp22's largest intron promotes tissue-specific expression of a linked reporter gene (44) . In addition, a putative enhancer at -162 kb demonstrates high occupancy of both H3K27ac and TEAD1 binding (29) . Therefore, it is likely that Pmp22-SE acts in concert with some combination of these elements to promote full levels of expression.
Interestingly, reduction from the Schwann cell-specific P1 promoter was robustly down-regulated by deletion of Pmp22-SE. ChIP-seq analysis of H3K27ac in oligodendrocytes, which weakly transcribe Pmp22 exclusively from the P2 promoter, indicated that Pmp22-SE's constituent enhancers are not active in this tissue (29) . Additionally, TEAD1, which has been shown to favor expression from the P1 promoter, binds prominently at the 'B' and 'C' sites within Pmp22-SE (29) . Taken together with our data, these results suggest that Pmp22-SE plays an important role in selection of the Schwann cell-specific promoter.
A previous study evaluating the importance of YY1 in peripheral nerve myelination showed that this transcription factor functions upstream of EGR2 (49) . The broad importance of EGR2 in myelination and Pmp22 transcriptional regulation may therefore explain why knockdown of YY1 induces down-regulation of Pmp22 transcription even in the absence of Pmp22-SE. As YY1 binds at the Pmp22 promoter, it is likely that some combination of these mechanisms governs Pmp22-SE-independent YY1 regulation of Pmp22.
While our data suggest a role in cell type-specific promoter usage, our in vitro system may not quantitatively recapitulate the role of the super-enhancers at specific developmental stages. However, as ChIP-seq data for H3K27 acetylation indicate that Pmp22-SE's constituent enhancers are established as early as postnatal day one and maintain this mark of activity through the peak period of myelination (29), we can speculate that Pmp22-SE plays an important role in developmental regulation by enabling the occupancy of postnatally regulated pro-myelination transcription factors like EGR2 and TEAD1. Future establishment of a rodent model bearing deletion of Pmp22-SE can shed light on the role of this super-enhancer in developmental upregulation and/or maintenance of Pmp22 transcription. is shown. Expression for each promoter/allele type combination was calculated using a relative standard curve constructed via serial dilutions of two independent pools of cDNA from the parent line. Error bars represent the standard deviation of three independent measurements for clones C1 and C3-C8 and two measurements for clone C2. Statistical analysis denotes results for biological replicates comparing the mean of the zero-deletion clones (n ¼ 5) to the mean of the two-deletion clones (n ¼ 3) (*P < 0.05).
In summary, deletion of an enhancer cluster shows a functional link between distal transcription factor binding sites and expression of a critical PNS myelin gene. These findings provide the first evidence that these distal regulatory elements are required for full Pmp22 transcription. Notably, several sites of high H3K27ac within Pmp22-SE are not associated with detectable binding of transcriptional regulators of Pmp22 such as EGR2 and SOX10; therefore, there are likely to be additional transcriptional regulators that support the high level of Pmp22 transcription in myelinating Schwann cells.
Materials and Methods
Super-enhancer peak calling and identification
Super-enhancer regions were determined by calling peaks in a Postnatal day 15 (P15) sciatic nerve H3K27ac ChIP-seq data set as described previously (26) , then combining enhancers occurring within 12.5 kb of each other into a single larger domain based off the strategy used by Whyte et al. (36) . Normalized reads for each region were ranked against the total number of peaks. Cutoff for super-enhancer designation was set at peaks with a tangent slope >1. The supplementary file lists those super-enhancers that exceed a threshold of >1000 normalized reads.
CRISPR construct design
CRISPR guide RNAs were designed using the E-CRISP design tool (52) . Oligonucleotides corresponding to identified target sequences were obtained from IDT and subcloned into the pX330 plasmid (53), purchased from Addgene. Sequences for guide RNA were as follows: GACAAGATGGGAATGAATCA and CTGTTCTAC CCTTACTTAGT (upstream site for clones C1-C8); GACCTTG AAGGAGCCCTGACA and CTGGAACTTCCTCGGGACTGT (upstream site, clones C9-C12); GTAAGAGAAGATTCAGGTAGG and CATTCTCTTCTAAGTCCATCC (downstream site).
Cell line culture and generation of CRISPR-Cas9-modified clonal populations
The S16 F2sN cell line was created by using genome editing to insert reporters downstream of the Pmp22 open reading frame as previously described (19) except that the cassette contained three open reading frames corresponding to firefly luciferase, secreted nanoluciferase and Neomycin resistance, each of which is preceded by the 2a ribosome stuttering sequence.
Cells from the S16 rat Schwann cell line-derived reporter line F2SN were cultured in DMEM supplemented with 4.5 g/l glucose, L-glutamine, penicillin, streptomycin and 5% bovine growth serum (Hyclone). F2SN cells were transfected with the pX330 plasmid containing our guide RNA sequence inserts. After 48 h, genomic DNA was collected from transfected populations and screened for detection of a PCR band corresponding to the post-repair junction. Primer sequences for guide RNA target site amplification were as follows: GCCGTCATCCGCATACTAAC and TGCACATTTTGGGATGTGTT (upstream site, clones C1-C8); GCTTTGGACACCAAGCAGTT and TGGCTTGGACACAGCTTAGA (upstream site, clones C9-C12); ACTCCAGAGTGGCGAGTCAT and GGCTTCCCTCTGTAGCTCCT (downstream site)." Populations in which this band could be detected were sorted via flow cytometry at the UW Carbone Cancer Center Flow Cytometry facility to isolate single cells. Genomic DNA from these clones was screened as above to detect clones possessing the intended deletion. Sanger sequencing was performed with the assistance of the UW-Madison Biotechnology Center to validate the expected repair junction.
Measurement of relative Pmp22-SE copy number
Relative copy number was evaluated using qPCR. Genomic DNA was harvested from confluent cells and assayed using a primer set within Pmp22-SE (TGGCTACAGCAGCTCTCCTT and AGTGGCTCGGTCCTTGACTA) and a primer set in the nearby extragenic space between Pmp22-SE and the Tekt3 gene (AGGGCCTCTTTCCTGAGAAC and TGGCTCTAAGGTCAGGG TGT). The comparative Ct method was used to calculate relative copy number (54) .
siRNA treatment
Cells were transfected with siRNA targeting Yy1 (Ambion, s128676) or a negative siRNA control (IDT, DS NC1) using the AMAXA 4D-Nucleofector system and SE Cell Line 4D-Nucleofector X Kit L reagents with program DS-138 (Lonza).
RT-qPCR
RNA was harvested from confluent cells or, for siRNA experiments, at 48h after transfection in triplicate using Tri Reagent (Ambion). RNA was converted to cDNA using the M-MLV reverse transcriptase (Invitrogen). cDNAs were analyzed by RT-qPCR using Power SYBR Green Master Mix (Thermo Fisher Scientific) on the StepOnePlus system or the ViiA7 system (Applied Biosystems). Relative expression was calculated using a relative standard curve or the Comparative Ct method (54) . Primers used are included in Table 1 . Note that for the Pmp22 reading frame experiment (Fig. 5) , an individual reverse primer targeting the 2a sequence was used.
Spectral karyotyping
Metaphase slide preparations were made from the S16 (ATCC (55, 56) . This technique is used to identify structural and numerical chromosome aberrations in this rat cell line.
Statistical analysis
P-values were obtained from the Student's two-tailed t-test (P < 0.05 is considered to be statistically significant).
Supplementary Material
Supplementary Material is available at HMG online. 
